GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Altman Z2-Score

Laekna (HKSE:02105) Altman Z2-Score : 8.23 (As of Apr. 01, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Laekna Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Laekna has a Altman Z2-Score of 8.23, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Laekna's Altman Z2-Score or its related term are showing as below:

HKSE:02105' s Altman Z2-Score Range Over the Past 10 Years
Min: -21.89   Med: -16.31   Max: 0.46
Current: 0.46

During the past 4 years, Laekna's highest Altman Z2-Score was 0.46. The lowest was -21.89. And the median was -16.31.


Laekna Altman Z2-Score Historical Data

The historical data trend for Laekna's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna Altman Z2-Score Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Altman Z2-Score
-16.31 -21.89 0.46 -

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Altman Z2-Score Get a 7-Day Free Trial -21.89 - 0.46 - -

Competitive Comparison of Laekna's Altman Z2-Score

For the Biotechnology subindustry, Laekna's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laekna's Altman Z2-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Laekna's Altman Z2-Score falls into.


;
;

Laekna Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Laekna's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.6926+3.26*0+6.72*-0.2617+1.05*5.184
=8.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was HK$1,025.01 Mil.
Total Current Assets was HK$868.45 Mil.
Total Current Liabilities was HK$158.52 Mil.
Retained Earnings was HK$0.00 Mil.
Pre-Tax Income was HK$-271.51 Mil.
Interest Expense was HK$-3.23 Mil.
Total Liabilities was HK$165.75 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(868.446 - 158.52)/1025.005
=0.6926

X2=Retained Earnings/Total Assets
=0/1025.005
=0

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-271.505 - -3.229)/1025.005
=-0.2617

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(859.254 - 0)/165.751
=5.184

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Laekna has a Altman Z2-Score of 8.23 indicating it is in Safe Zones.


Laekna  (HKSE:02105) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Laekna Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Laekna's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Laekna Business Description

Traded in Other Exchanges
Address
No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Lu Chris Xiangyang 2501 Other
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Laekna Wonderland Limited 2101 Beneficial owner
Orbimed Advisors Iii Limited 2102 Investment manager
Orbimed Asia Partners Iii, L.p. 2102 Investment manager
Orbimed Asia Gp Iii, L.p. 2102 Investment manager
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Liu Zeng 2201 Interest of corporation controlled by you
Ealex Llc 2101 Beneficial owner
Xie Ling 2501 Other

Laekna Headlines

No Headlines